WO2020099925A3 - Peptides and pharmaceutical compositions for treating eye diseases - Google Patents

Peptides and pharmaceutical compositions for treating eye diseases Download PDF

Info

Publication number
WO2020099925A3
WO2020099925A3 PCT/IB2019/001220 IB2019001220W WO2020099925A3 WO 2020099925 A3 WO2020099925 A3 WO 2020099925A3 IB 2019001220 W IB2019001220 W IB 2019001220W WO 2020099925 A3 WO2020099925 A3 WO 2020099925A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical compositions
eye diseases
peptides
treating eye
peptide compounds
Prior art date
Application number
PCT/IB2019/001220
Other languages
French (fr)
Other versions
WO2020099925A2 (en
Inventor
Taegon Baik
Jong-Yun Choi
Gyoung-Wook MIN
Original Assignee
Yuyu Pharma, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yuyu Pharma, Inc. filed Critical Yuyu Pharma, Inc.
Priority to KR1020217018226A priority Critical patent/KR20210087539A/en
Priority to AU2019378162A priority patent/AU2019378162A1/en
Priority to MX2021005077A priority patent/MX2021005077A/en
Priority to JP2021526304A priority patent/JP7522732B2/en
Priority to CN201980078779.XA priority patent/CN113474356A/en
Priority to SG11202104178TA priority patent/SG11202104178TA/en
Priority to EP19883897.1A priority patent/EP3880690A4/en
Priority to CA3119921A priority patent/CA3119921A1/en
Priority to BR112021009341-9A priority patent/BR112021009341A2/en
Publication of WO2020099925A2 publication Critical patent/WO2020099925A2/en
Publication of WO2020099925A3 publication Critical patent/WO2020099925A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Immunology (AREA)

Abstract

The present invention relates to novel peptides and a pharmaceutical compositions comprising the same. The peptide compounds and compositions disclosed herein are useful as therapeutic agents for treating eye diseases. When administered to the eyes, the peptide compounds and compositions disclosed herein increase the amount of tear secretion and promotes recovery of a damaged cornea.
PCT/IB2019/001220 2018-11-14 2019-11-14 Peptides and pharmaceutical compositions for treating eye diseases WO2020099925A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
KR1020217018226A KR20210087539A (en) 2018-11-14 2019-11-14 Peptides and pharmaceutical compositions for treating eye diseases
AU2019378162A AU2019378162A1 (en) 2018-11-14 2019-11-14 Peptides and pharmaceutical compositions for treating eye diseases
MX2021005077A MX2021005077A (en) 2018-11-14 2019-11-14 Peptides and pharmaceutical compositions for treating eye diseases.
JP2021526304A JP7522732B2 (en) 2018-11-14 2019-11-14 Peptides and pharmaceutical compositions for treating eye diseases
CN201980078779.XA CN113474356A (en) 2018-11-14 2019-11-14 Peptides and pharmaceutical compositions for the treatment of ocular diseases
SG11202104178TA SG11202104178TA (en) 2018-11-14 2019-11-14 Peptides and pharmaceutical compositions for treating eye diseases
EP19883897.1A EP3880690A4 (en) 2018-11-14 2019-11-14 Peptides and pharmaceutical compositions for treating eye diseases
CA3119921A CA3119921A1 (en) 2018-11-14 2019-11-14 Peptides and pharmaceutical compositions for treating eye diseases
BR112021009341-9A BR112021009341A2 (en) 2018-11-14 2019-11-14 peptides and pharmaceutical compositions for the treatment of eye diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862767180P 2018-11-14 2018-11-14
US62/767,180 2018-11-14

Publications (2)

Publication Number Publication Date
WO2020099925A2 WO2020099925A2 (en) 2020-05-22
WO2020099925A3 true WO2020099925A3 (en) 2020-06-25

Family

ID=70732068

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2019/001220 WO2020099925A2 (en) 2018-11-14 2019-11-14 Peptides and pharmaceutical compositions for treating eye diseases

Country Status (11)

Country Link
EP (1) EP3880690A4 (en)
JP (1) JP7522732B2 (en)
KR (1) KR20210087539A (en)
CN (1) CN113474356A (en)
AU (1) AU2019378162A1 (en)
BR (1) BR112021009341A2 (en)
CA (1) CA3119921A1 (en)
MX (1) MX2021005077A (en)
SG (1) SG11202104178TA (en)
TW (1) TW202031675A (en)
WO (1) WO2020099925A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019013799A (en) 2017-05-17 2020-08-13 Yuyu Pharma Inc Novel peptide and pharmaceutical composition for treatment of eye diseases comprising same novel peptide as active ingredient.
US11613558B2 (en) 2018-11-14 2023-03-28 Yuyu Pharma, Inc. Peptides and pharmaceutical compositions for treating eye diseases
KR102662922B1 (en) * 2022-05-31 2024-05-03 주식회사 세네릭스 Novel D-amino acid derivatives and compositions comprising the same

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6037135A (en) * 1992-08-07 2000-03-14 Epimmune Inc. Methods for making HLA binding peptides and their uses
WO2017175963A1 (en) * 2016-04-08 2017-10-12 주식회사 아이바이오코리아 Chondrocyte extracellular matrix-derived peptide
KR101795653B1 (en) * 2016-05-19 2017-11-09 인제대학교 산학협력단 Composition for inhibiting angiogenesis comprising chimeric protein of collagen type II peptide-Aflibercept
KR20180074928A (en) * 2016-12-26 2018-07-04 주식회사 아이바이오코리아 Animal medicine composition for preventing or treating dry eye
WO2018225961A1 (en) * 2017-05-17 2018-12-13 주식회사 유유제약 Novel peptide and pharmaceutical composition for treatment of eye diseases comprising same novel peptide as active ingredient

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101690539B1 (en) * 2015-07-30 2016-12-29 주식회사 아이바이오코리아 Pharmaceutical composition for preventing or treating dry eye

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6037135A (en) * 1992-08-07 2000-03-14 Epimmune Inc. Methods for making HLA binding peptides and their uses
WO2017175963A1 (en) * 2016-04-08 2017-10-12 주식회사 아이바이오코리아 Chondrocyte extracellular matrix-derived peptide
KR101795653B1 (en) * 2016-05-19 2017-11-09 인제대학교 산학협력단 Composition for inhibiting angiogenesis comprising chimeric protein of collagen type II peptide-Aflibercept
KR20180074928A (en) * 2016-12-26 2018-07-04 주식회사 아이바이오코리아 Animal medicine composition for preventing or treating dry eye
WO2018225961A1 (en) * 2017-05-17 2018-12-13 주식회사 유유제약 Novel peptide and pharmaceutical composition for treatment of eye diseases comprising same novel peptide as active ingredient

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SHANKAR, G. ET AL.,: "Structural determinants of calcium signaling by RGD peptides in rat osteoclasts: integrin-dependent and-independent actions", EXPERIMENTAL CELL RESEARCH, vol. 219, 1 January 1995 (1995-01-01), pages 364 - 371, XP055714628 *

Also Published As

Publication number Publication date
CN113474356A (en) 2021-10-01
AU2019378162A1 (en) 2021-05-20
MX2021005077A (en) 2021-08-11
KR20210087539A (en) 2021-07-12
JP2022507404A (en) 2022-01-18
TW202031675A (en) 2020-09-01
SG11202104178TA (en) 2021-05-28
EP3880690A2 (en) 2021-09-22
BR112021009341A2 (en) 2021-08-10
EP3880690A4 (en) 2023-09-13
WO2020099925A2 (en) 2020-05-22
JP7522732B2 (en) 2024-07-25
CA3119921A1 (en) 2020-05-22

Similar Documents

Publication Publication Date Title
WO2020099925A3 (en) Peptides and pharmaceutical compositions for treating eye diseases
MX2019013799A (en) Novel peptide and pharmaceutical composition for treatment of eye diseases comprising same novel peptide as active ingredient.
WO2018033792A3 (en) Ophthalmic pharmaceutical compositions and uses relating thereto
FI3811943T3 (en) Compound for use in the treatment of ocular disorders
MX2016014634A (en) Compounds for treating ophthalmic diseases and disorders.
WO2018067217A3 (en) Compositions comprising pedf-derived short peptides and uses thereof
AU2015205188A1 (en) Pharmaceutical preparation containing pyridylamino acetic acid compound
WO2015183963A3 (en) Therapeutic compositions including redox-active parabenzoquinones and uses thereof
AU2018218696B2 (en) Composition for the prevention or the treatment of visual impairments comprising ursodeoxycholic acid
PH12021550039A1 (en) 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same
RU2010110544A (en) APPLICATION OF SUBSTANCES FOR THE TREATMENT OF VISION LOSS IN PEOPLE WITH A DEAF AND OTHER DEGENERATIVE EYE DISEASES
MX2020009132A (en) Pharmaceutical compositions comprising nebivolol.
EA202191684A1 (en) DRUG CONTAINING URSODEOXYCHOLIC ACID FOR TREATMENT OR PREVENTION OF PRESBIOPIA
CR20220096A (en) Therapeutic fusion proteins
MX2020010078A (en) Pharmaceutical composition comprising timolol.
MY178169A (en) Topical ophthalmic peptide formulation
MX2021014000A (en) Triamcinolone acetonide-loaded liposomes topical ophthalmic formulations for prevention of macular thickening and its associated visual outcomes after lens surgery.
WO2017152129A3 (en) Treatment of glaucoma and/or retinal diseases and formulations useful therefore
PH12020550722A1 (en) Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye
AU2017261303A1 (en) Ophthalmic compositions
WO2016130518A3 (en) Methods and compositions for treating muscle disease and disorders
MX2022006523A (en) Composition comprising budesonide for ophthalmic use.
RU2014106328A (en) PHARMACEUTICAL COMPOSITIONS CONTAINING 4-BROM-N- (IMIDAZOLIDIN-2-YLIDENE) -1H-BENZIMIDAZOL-5-AMINE FOR THE TREATMENT OF RETAIL DISEASES
HK1253191A2 (en) Novel artificial tears containing recombinant human lysozyme and recombinant human epidermal growth factor
RU2009134539A (en) VACCINOTHERAPY OF NEOVASCULARIZATION OF THE VASCULAR EYE

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19883897

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2021526304

Country of ref document: JP

Kind code of ref document: A

Ref document number: 3119921

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2019378162

Country of ref document: AU

Date of ref document: 20191114

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112021009341

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 20217018226

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2019883897

Country of ref document: EP

Effective date: 20210614

ENP Entry into the national phase

Ref document number: 112021009341

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20210513